{"analyses":[{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.90","estimateComment":"Stratified by: PD-L1 status (≥ 1% vs \\<1%/not evaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.66"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.74","upperLimit":"56.80","value":"36.76"},{"comment":"Insufficient number of participants with events","groupId":"OG001","lowerLimit":"49.02","upperLimit":"NA","value":"64.66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"TTDM is defined as the time between the date of randomization and the first date of distant metastasis or the date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax using blinded independent central review (BICR) according to response evaluation criteria in solid tumors (RECIST) 1.1. Patients who have not developed distant metastasis or died at the time of analysis will be censored on the date of their last evaluable tumor assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG000","title":"Arm B: Platinum Doublet Chemo"},{"description":"Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG001","title":"Arm C: Nivo 360 mg + Platinum Doublet Chemo"}],"paramType":"MEDIAN","populationDescription":"All concurrently randomized participants in Arm C and Arm B","reportingStatus":"POSTED","timeFrame":"From randomization to the first date of distant metastasis or the date of death in the absence of distant metastasis (Up to approximately 84 months)","title":"Time to Death or Distant Metastases (TTDM)","type":"SECONDARY","unitOfMeasure":"Months"}